Coronavirus, ISS: “It will be a Covid Christmas. The third wave will depend on the behavior in the holidays”



[ad_1]

There is no doubt: “It will be a Covid Christmas”, says the president of the Higher Institute of Health, Silvio Brusaferro at a press conference at the Ministry of Health, “although we have more yellow regions.” “A Christmas that we hope will be unique and we hope that it will last with respect to the history that we will live,” he adds. This means organizing ourselves avoiding aggregations in the most decisive way possible. The following waves are not written in the stars but in the way in which we we will behave. Avoid them, considering that the most fragile people risk more ”.

Coronavirus, bulletin for December 1 today, 19,350 new cases with 182,100 swabs. The victims are 785



“Today the number of new cases is decreasing but it is still very high. We have to go down significantly, otherwise it becomes very difficult to control. The goal is to move from the mitigation phase to the containment phase, and this step requires significantly fewer cases. new cases daily. What we are at Christmas will depend on how the curve changes: if it goes down and how fast it goes down ”, explains Brusaferro.

“There are no shortcuts, we know how this virus is transmitted and we know what are the measures that interrupt or reduce the possibility of contagion, when we violate the measures we facilitate the circulation of the virus. A fact that cannot be ignored,” he emphasizes.

Covid, Brusaferro: ” Short times for the vaccine, but without exception to safety ”


And if the restrictions are of the present, the ISS looks to the future, that future called vaccines: “There will be no security exemptions,” says Brusaferro. “There was an extraordinary effort in a very short time – he adds – to be able to develop anti-covid vaccines, but this does not mean that they renounce the safety procedures that will be examined by the regulatory bodies, for Europe it will be the ‘Ema, as the corresponding files are sent by the manufacturing companies ”.

The plan will be presented tomorrow by the Minister of Health, Roberto Speranza. On the roadmap, however, it is already known that the green light for Pfizer (and to follow the other companies) should arrive at the end of December, probably the 29th. A month later the campaign for Italy will begin. And the bites will proceed for the entire population, probably on a voluntary basis, starting with health personnel, with the highest risk. The general director of Prevention of the Ministry of Health, Gianni Rezza, also explains: “The deadlines in which the doses will arrive will also be dictated by the authorizations of the regulatory bodies. Once they give the green light based on efficacy and safety data at that time, we can have a first limited number of doses and then more and more, as established. The post-marketing pharmacovigilance phase will be carried out as for all other vaccines that are authorized and marketed. last days, weeks, months, years, but valid for these vaccines as for all others. But when the vaccine goes on the market it will have passed the phase 3 efficacy tests in 30-40-50 thousand people ”.

Pfizer: “Application for European authorization for the vaccine against Covid”. The Ema: “Possible ok on December 29”

by Elena Dusi



As for studies, “Covid reinfection cases have been reported,” they are also “extremely rare,” says Rezza. “One study had highlighted the level of antibody decline, but other studies have shown that the level of antibodies remains unchanged: it is likely that this also depended on the method of antibody detection. However, there is a study from the institute of health – explains – that he highlighted that the antibodies developed against the ‘spike’ protein remain over time and this, taking into account that vaccines are based on the antibody response of the ‘spike’ protein, seems to us to be comforting news. Therefore If we first waited to understand the protection capacity of vaccines, now we can say that there will be protection, but it will be a question of whether it will be appropriate to make a reinforcement, as many vaccines provide ”.

[ad_2]